Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN

Leinung,Martin; Hirth,Daniel; Tahtali,Aykut; Diensthuber,Marc; Stöver,Timo; Wagenblast,Jens

doi:10.3892/ol.2012.927

Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN

Authors:
- Martin Leinung
- Daniel Hirth
- Aykut Tahtali
- Marc Diensthuber
- Timo Stöver
- Jens Wagenblast
View Affiliations

Affiliations: ENT Department, Medical School, Goethe University, Frankfurt am Main, Germany
Published online on: September 20, 2012 https://doi.org/10.3892/ol.2012.927
Pages: 1305-1308

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibition of the proteasome with Bortezomib as well as inhibition of Polo-like-kinase-1 (PLK-1) has been shown to be effective in many solid tumour models and also in squamous cell carcinoma of the head and neck (SCCHN) cell lines. For the first time, we systematically examined the antitumour effect of Bortezomib in combination with BI2536 in SCCHN in an in vitro study. Dose escalation studies were performed with nine SCCHN cell lines using Bortezomib and BI2536 as single agent and combination treatments. Growth-inhibitory and pro-apoptotic effects were measured quantitatively using cytohistology and Human Apoptose Array kit. The combination of Bortezomib and BI2536 showed significant anti-proliferative and apoptotic activity in all SCCHN cell lines investigated (P=0.008) compared to both the untreated control group and Bortezomib alone. A combination treatment regime consisting of the proteasome inhibitor, Bortezomib, and the inhibitor of PLK-1, BI2536, leads to an enhanced anti-proliferative and apoptotic effect in SCCHN cell lines, compared to single agent treatment with Bortezomib alone.

View Figures

View References

1.	A JemalR SiegelE WardY HaoJ XuMJ ThunCancer statistics, 2009CA Cancer J Clin59225249200910.3322/caac.20006
2.	A ForastiereW KochA TrottiD SidranskyHead and neck cancerN Engl J Med34518901900200110.1056/NEJMra001375
3.	MK GibsonAA ForastiereReassessment of the role of induction chemotherapy for head and neck cancerLancet Oncol7565574200610.1016/S1470-2045(06)70757-416814208
4.	P SpecenierJB VermorkenCetuximab in the treatment of squamous cell carcinoma of the head and neckExpert Rev Anticancer Ther11511524201110.1586/era.11.2021504318
5.	MK GibsonY LiB MurphyMH HussainRC DeContiJ EnsleyRandomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology GroupJ Clin Oncol2335623567200510.1200/JCO.2005.01.05715908667
6.	B BurtnessMA GoldwasserW FloodB MattarAA ForastierePhase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyJ Clin Oncol2386468654200510.1200/JCO.2005.02.4646
7.	J WagenblastM HambekM BaghiW GstottnerK StrebhardtH AckermannAntiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell linesJ Cancer Res Clin Oncol134323330200810.1007/s00432-007-0287-917701215
8.	J WagenblastM BaghiC ArnoldnerS BisdasW GstottnerH AckermannCetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell linesJ Cancer Res Clin Oncol135387393200910.1007/s00432-008-0477-018830627
9.	PL ZhangPK PellitteriA LawPA GilroyGC WoodTL KennedyOverexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosisMod Pathol18924932200510.1038/modpathol.380037215920558
10.	CH ChungJS ParkerK ElyJ CarterY YiBA MurphyGene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinomaCancer Res6682108218200616912200
11.	J AdamsVJ PalombellaEA SausvilleJ JohnsonA DestreeDD LazarusProteasome inhibitors: a novel class of potent and effective antitumor agentsCancer Res5926152622199910363983
12.	P SchoffskiPolo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncologyOncologist14559570200910.1634/theoncologist.2009-001019474163
13.	P SchoffskiJY BlayJ De GreveE BrainJP MachielsJC SoriaMulticentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)Eur J Cancer46220622152010
14.	D DattaP BanerjeeM GasserAM Waaga-GasserS PalCXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1J Biol Chem2853684236848201010.1074/jbc.M110.17032420855888
15.	RB RayA RaychoudhuriR SteeleP NerurkarBitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosisCancer Res7019251931201010.1158/0008-5472.CAN-09-343820179194
16.	M LunPL ZhangPK PellitteriA LawTL KennedyRE BrownNuclear factor-κB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and validation in human cell lines using Velcade and siRNA/N molecular F-κBAnn Clin Lab Sci352512582005
17.	JB SunwooZ ChenG DongN YehC Crowl BancroftE SausvilleNovel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinomaClin Cancer Res7141914282001
18.	A FribleyQ ZengCY WangProteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cellsMol Cell Biol2496959704200410.1128/MCB.24.22.9695-9704.2004
19.	C LiR LiJR GrandisDE JohnsonBortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cellsMol Cancer Ther716471655200810.1158/1535-7163.MCT-07-244418566236
20.	C AllenK SaigalL NottinghamP ArunZ ChenC Van WaesBortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alter-native nuclear factor-κB subunits in head and neck cancerClin Cancer Res1441754185200818593997
21.	C Van WaesAA ChangPF LebowitzCH DruzgalZ ChenYA ElsayedInhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinomaInt J Radiat Oncol Biol Phys63140014122005
22.	A ArgirisAG DuffyS KummarNL SimoneY AraiSW KimEarly tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancerClin Cancer Res1757555764201110.1158/1078-0432.CCR-11-086121750205
23.	C LiY ZangM SenRJ Leeman-NeillDS ManJR GrandisBortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell deathMol Cancer Ther822112220200910.1158/1535-7163.MCT-09-032719638453
24.	NB DavisDA TaberRH AnsariCW RyanC GeorgeEE VokesPhase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium studyJ Clin Oncol22115119200410.1200/JCO.2004.07.16514701773
25.	CN PapandreouDD DalianiD NixH YangT MaddenX WangPhase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerJ Clin Oncol2221082121200410.1200/JCO.2004.02.10615169797
26.	MH ShahD YoungHL KindlerI WebbB KleiberJ WrightPhase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumorsClin Cancer Res1061116118200410.1158/1078-0432.CCR-04-042215447997